<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="48120">Anthracycline</z:chebi> chemotherapeutic agents of the topoisomerase inhibitor family are widely used for the treatment of various <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>While targeted <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues are generally situated in a hypoxic environment, the connection between efficacy of <z:chebi fb="0" ids="48120">anthracycline</z:chebi> agents and cellular <z:mp ids='MP_0005039'>hypoxia</z:mp> response has not been investigated in depth </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we report that <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> (DXR) impairs the transcriptional response of the <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor (HIF) by inhibiting the binding of the HIF-heterodimer to the consensus -RCGTG- enhancer element </plain></SENT>
<SENT sid="3" pm="."><plain>This pleiotropic effect retarded migration of von Hippel-Lindau (VHL)-defective <z:hpo ids='HP_0005584'>renal cell carcinoma</z:hpo> (<z:chebi fb="60" ids="47899">RCC</z:chebi>) and that of VHL-competent <z:chebi fb="60" ids="47899">RCC</z:chebi> in <z:mp ids='MP_0005039'>hypoxia</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>This effect was accompanied by a co-ordinated downregulation of HIF target <z:chebi fb="0" ids="32568">lysyl</z:chebi>-oxidase (LOX) family members LOX, LOX-like2 (LOXL2), and LOXL4 </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, DXR suppressed HIF-target genes in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenografts, inhibited cardiac induction of HIF targets in rats with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001903'>anemia</z:hpo>, and impaired the angiogenic response in the <z:chebi fb="0" ids="6046">isoproterenol</z:chebi>-induced <z:hpo ids='HP_0001635'>heart failure</z:hpo> model, which may account for the clinical fragility of <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Collectively, these findings highlight the impaired <z:mp ids='MP_0005039'>hypoxia</z:mp> response by <z:chebi fb="0" ids="48120">anthracycline</z:chebi> agents affecting both <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and organs of the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> host and offer a promising opportunity to develop HIF-inhibitors using DXR as a chemical template </plain></SENT>
</text></document>